CEO and MD Christina Holgate tells CNBC why the Supplement brand Blackmores decided to open its first retail store.
Health groups called for Turing Pharmaceuticals to follow through on its promise to lower the price of a recently acquired drug.
CNBC's Meg Tirrell reports a number of health groups have appealed to Turing Pharmaceuticals asking the company to lower its drug price of Daraprim.
Spark Therapeutics is working on an experimental gene therapy for an inherited eye disorder, and it has the potential to be the first gene therapy on the market in the U.S.
Spark Therapeutics' gene therapy for rare, inherited forms of blindness met the goals of a late-stage study.
AbbVie said its experimental drug improved symptoms of rheumatoid arthritis in patients in two mid-stage studies.
CNBC's Meg Tirrell speaks to Alnylam Pharmaceuticals CEO John Maraganore, about drug pricing in the U.S.
Democratic presidential candidate Hillary Clinton unveils her plan to lower prescription drug costs.
Democratic presidential candidate Hillary Clinton addresses innovation in the pharmaceutical and biotech industries, and unveils her plan to lower prescription drug costs.
Dr. Peter Bach, MD of Memorial Sloan Kettering Cancer Center, weighs in on Turing Pharmaceuticals' decision to increase a single dose of Daraprim from $13.50 to $750.
CNBC's Meg Tirrell reports on Hillary Clinton's drug plan, one day after she criticized drug price gouging.
Hillary Clinton is criticizing drug price gouging. Steve Case, Revolution Chairman and CEO, shares his take.
Hillary Clinton is criticizing drug price gouging, after news a drug company hiked the price of one of its drugs by 5,000 percent overnight, with CNBC's Meg Tirrell.
CNBC's Jane Wells reports from Arcata, California, where the city council wants to build the country's first marijuana innovation zone.
A new government study on blood pressure found potentially lifesaving results, reports CNBC's Meg Tirrell.
Disappointing clinical results for GSK-Theravance respiratory treatment.
Amgen wins FDA approval for cholesterol-lowering drug Repatha.
Abbott denies FT speculation about a St. Jude's acquisition.
Shares of Valeant are down 6 percent after buying Sprout Pharmaceuticals, the maker of the "female Viagra" drug. CNBC's Meg Tirrell discusses drug deals.
Valeant to purchase flibanserin-maker Sprout for $1 billion.